These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30760538)

  • 21. Proteomic analysis for early detection of ovarian cancer: a realistic approach?
    Stevens EV; Liotta LA; Kohn EC
    Int J Gynecol Cancer; 2003; 13 Suppl 2():133-9. PubMed ID: 14656269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma proteomic pattern as biomarkers for ovarian cancer.
    Lin YW; Lin CY; Lai HC; Chiou JY; Chang CC; Yu MH; Chu TY
    Int J Gynecol Cancer; 2006; 16 Suppl 1():139-46. PubMed ID: 16515582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
    Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
    Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer.
    Tajmul M; Parween F; Singh L; Mathur SR; Sharma JB; Kumar S; Sharma DN; Yadav S
    Int J Biol Macromol; 2018 Mar; 108():503-514. PubMed ID: 29222021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry.
    Elschenbroich S; Ignatchenko V; Clarke B; Kalloger SE; Boutros PC; Gramolini AO; Shaw P; Jurisica I; Kislinger T
    J Proteome Res; 2011 May; 10(5):2286-99. PubMed ID: 21491939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteomics of microparticles with SILAC Quantification (PROMIS-Quan): a novel proteomic method for plasma biomarker quantification.
    Harel M; Oren-Giladi P; Kaidar-Person O; Shaked Y; Geiger T
    Mol Cell Proteomics; 2015 Apr; 14(4):1127-36. PubMed ID: 25624350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.
    Kong F; Nicole White C; Xiao X; Feng Y; Xu C; He D; Zhang Z; Yu Y
    Gynecol Oncol; 2006 Feb; 100(2):247-53. PubMed ID: 16229881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive modeling in proteomics-based disease detection.
    Pham TD
    Annu Int Conf IEEE Eng Med Biol Soc; 2007; 2007():3308-11. PubMed ID: 18002703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel proteomic technologies to address gaps in pre-clinical ovarian cancer biomarker discovery efforts.
    Jordan HA; Thomas SN
    Expert Rev Proteomics; 2023; 20(12):439-450. PubMed ID: 38116719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
    Swiatly A; Horala A; Hajduk J; Matysiak J; Nowak-Markwitz E; Kokot ZJ
    BMC Cancer; 2017 Jul; 17(1):472. PubMed ID: 28683725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liquid biopsy in ovarian cancer: recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression.
    Chang L; Ni J; Zhu Y; Pang B; Graham P; Zhang H; Li Y
    Theranostics; 2019; 9(14):4130-4140. PubMed ID: 31281536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovarian cancer: can proteomics give new insights for therapy and diagnosis?
    Toss A; De Matteis E; Rossi E; Casa LD; Iannone A; Federico M; Cortesi L
    Int J Mol Sci; 2013 Apr; 14(4):8271-90. PubMed ID: 23591842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
    Nossov V; Amneus M; Su F; Lang J; Janco JM; Reddy ST; Farias-Eisner R
    Am J Obstet Gynecol; 2008 Sep; 199(3):215-23. PubMed ID: 18468571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature.
    Posadas EM; Davidson B; Kohn EC
    Curr Opin Oncol; 2004 Sep; 16(5):478-84. PubMed ID: 15314519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovarian cancer: biomarker proteomic diagnosis in progress.
    Zhang Y; Guo B; Bi R
    Appl Biochem Biotechnol; 2012 Oct; 168(4):910-6. PubMed ID: 22945560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer.
    Baggerly KA; Morris JS; Edmonson SR; Coombes KR
    J Natl Cancer Inst; 2005 Feb; 97(4):307-9. PubMed ID: 15713966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis of early relapse in ovarian cancer using serum proteomic profiling.
    Oh JH; Gao J; Nandi A; Gurnani P; Knowles L; Schorge J
    Genome Inform; 2005; 16(2):195-204. PubMed ID: 16901102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum proteomic pattern analysis for early cancer detection.
    Liu Y
    Technol Cancer Res Treat; 2006 Feb; 5(1):61-6. PubMed ID: 16417403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantifiable TCR repertoire changes in prediagnostic blood specimens among patients with high-grade ovarian cancer.
    Yu X; Pan M; Ye J; Hathaway CA; Tworoger SS; Lea J; Li B
    Cell Rep Med; 2024 Jul; 5(7):101612. PubMed ID: 38878776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer.
    Claussen C; Rausch AV; Lezius S; Amirkhosravi A; Davila M; Francis JL; Hisada YM; Mackman N; Bokemeyer C; Schmalfeldt B; Mahner S; Langer F
    Thromb Res; 2016 May; 141():39-48. PubMed ID: 26967531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.